Targovax announces today that the clinical trial with TG01 in operable pancreatic cancer now has reached Phase IIa. Promising Phase I-results triggered a 12.5 MNOK milestone, committed in 2012, from current owners. TG01, a RAS mutation-targeted medicine, is used in combination with chemotherapy. The trial is expanding from OUS Radiumhospitalet, the Clinical Trials Unit, to also include two sites in UK, namely The Christie NHS Foundation Trust in Manchester, and The Clatterbridge Cancer Centre NHS Foundation Trust in Liverpool.
In the TG01 clinical trial, patients start treatment 1-8 weeks after surgery of pancreatic cancer.
A patent application with priority 2013 provides the base for expanding pipeline to broader indications. Pipeline drug candidates will cover 99% of the RAS-positive cancers, the cancer medicine TG02 will initially be developed for colorectal and lunc (NSCLC) cancers.
Targovax's RAS specific immunotherapy triggers both cytotoxic and helper T-cell responses, educating the patients' immune system to recognize and kill the cancer cells.